Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 26;28(1):5.
doi: 10.1007/s11102-024-01490-0.

Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland

Carlos Alcaide  1 , Francisco Perez  2 , Francisco Esteban  3 , Miguel Muñoz  4
Affiliations

Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland

Carlos Alcaide et al. Pituitary. .

Abstract

Background: Human adamantinomatous craniopharyngioma (ACP) is a brain tumor that originates at the base of the skull and shows aggressive local behavior, invading sensitive structures such as the optic pathways and hypothalamus. The conventional treatment of the tumor has been surgery and radiotherapy with the consequent development of serious sequelae. It is well known that Substance P (SP) peptide and Neurokinin-1 receptor (NK-1R) are involved in inflammation and cancer progression and its blockage with NK-1R antagonists has been shown to effectively counteract tumor development in preclinical trials. The oncogenic mechanism underlying ACP is based on a secretory phenotype associated with the production of paracrine biomarkers that establish an inflammatory and angiogenic microenvironment for the progression of ACP.

Methods: With the aim of describing the existence and distribution of SP/NK-1R in the ACP, we studied by immunohistochemistry the expression of SP and NK-1R in 43 human ACP and compared with healthy pituitary gland samples.

Results: SP and the NK-1R were overexpressed in all ACP more than in pituitary glands samples. SP expression is found widespread the ACP and is preferentially localized in the nucleus than in cytoplasm of tumor cells. Likewise, areas of glial reaction and endothelial cells also express SP preferentially in the cell nuclei. NK-1R is expressed mainly in the glial reaction, especially in the nuclei and membranes of its inflammatory cells and less prominently in the cytoplasm. In ACP neovessels, NK-1R is expressed in endothelial cells and fibroblasts that constitute their basement membranes. Tumor cells did not show significant NK-1R expression.

Conclusions: These findings, reported here for the first time, suggest a role for SP and NK-1R in pituitary gland and ACP and opens the door to future clinical trials on treatment with NK-1R antagonist drugs in ACP patients.

Keywords: Craniopharyngioma; Immunohistochemistry; Neurokinin-1 receptor; Pituitary gland; Substance P.

PubMed Disclaimer

Conflict of interest statement

Declarations. Informed consent: Not applicable. Institutional review board statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Medical Research Ethics Committee of Hospitales Universitarios Virgen Macarena-Virgen Del Rocío. Committee that has weighted and evaluated in session held on 26thApril 2018 and collected in minutes 05/2018. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Martinez-Barbera JP, Buslei R (2015) Adamantinomatous craniopharyngioma: Pathology, molecular genetics and mouse models. J Pediatr Endocrinol Metab 28(1–2):7–17 - PubMed
    1. Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S, Craniopharyngioma (2019) Nat Rev Dis Prim. 5(1)
    1. Müller HL, Merchant TE, Puget S, Martinez-Barbera JP (2017) New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol 13(5):299–312. https://doi.org/10.1038/nrendo.2016.217 - DOI - PubMed
    1. Karavitaki N, Cudlip S, Adams CBT, Wass JAH (2006) Craniopharyngiomas Endocr Rev 27(4):371–397 - DOI - PubMed
    1. Boekhoff S, Bison B, Eveslage M, Sowithayasakul P, Müller HL (2019) Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007. Pituitary 22(5):532–541. https://doi.org/10.1007/s11102-019-00983-7 - DOI - PubMed

LinkOut - more resources